Unconventional Capital Wisdom
Value, long-term horizon, worldly wisdom, growth at reasonable price

Kindred Bioscience: Significant Upside From Our Best Friends

Executive summary:

  • Companion animal market is growing and drug development is in its infancy.
  • Companion animal drug development needs significantly lower R&D costs and takes half the time of human drug development with lower risk.
  • Kindred management and team has significant biologic development experience that allows them to develop drugs in house while competitors use outsourcing.
  • Kindred CEO Richard Chin and Seth Klarman's Baupost both own significant stakes.
  • We see potential upside around 50-60% by late 2014 if CereKin, AtoKin and SentiKin NADA filings are submitted on schedule and FDA approval is received by early 2015.


Company Overview

Kindred Bioscience (NASDAQ:KIN) is a California based company that focuses on the development of companion animal drugs. They utilize...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details